Physician profile
Daniel J Sabol
NPI 1740376177
$1,832.85
in general payments reported to CMS, 2019-2025
21 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.73 · 2020: $47.98 · 2021: $196 · 2022: $269 · 2023: $417 · 2024: $397 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.98 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $408.35 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $281.88 | 2022-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $215.56 | 2022-2025 | Farxiga, Breztri |
| Pfizer INC. | $169.13 | 2023-2025 | |
| Novo Nordisk INC | $128.97 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $68.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $68.58 | 2021-2023 | Freestyle Libre, Freestyle Libre 3 |
| Astellas Pharma US INC | $64.26 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $59.03 | 2023-2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $56.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.47 | 2021-2022 | |
| Viatris Specialty LLC | $50.85 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $38.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.04 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $29.10 | 2023-2025 | Shingrix, Arexvy, Bexsero |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.07 | 2024 | Rexulti |
| Dexcom, INC. | $18.90 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.48 | 2025 | Xifaxan |
| Relievant Medsystems, INC. | $13.13 | 2023 | Intracept |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sabol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.